American Diversified Holdings Corporation (ADHC) to Focus on Medical Wireless Device Application Market for 2013

ADHC Poised to Capture Market Share in $58 Billion mHealth Market

DEL MAR, CA–(Marketwire – January 10, 2013) –  American Diversified Holdings Corporation (ADHC) has refocused its corporate direction and is in the processing of creating a secure mobile application platform in the mHealth arena specifically designed for the Apple® iPhone™ , iPod touch™, iPad™ and other mobile platforms including the Android™ platform developed by Google®.

Management has been working with leading developers and expects to unveil products capable of generating significant revenue in the 2nd quarter of 2013. Remote Health Monitoring Systems, Electronic Medical Records and Personalized Medicine are the areas of the Health Care sector that ADHC’s team is currently addressing for the mobile applications market.

The latest report from market research firm Gartner indicated the Mobile Apps Markets is poised for continued growth for 2014 predicting 185 billion downloaded, for a total of $58 billion in revenue.

The healthcare industry is among the fastest growing handheld device markets. The total market for handheld devices in healthcare reached $8.8 billion in 2010, a 7% increase from 2009. The estimated market in the mobile health care sector are estimated to grow in line with the general market estimates.

“We are excited to be at the forefront of the development of secure mobile software that will aid in the collection, analyzing and presentation of data for the healthcare market. Our technology partners have been developing software in the security and data protection markets for over ten years and we look forward to taking that expertise into the mobile platform market. We are very optimistic that we can work with the Healthcare Industry and Healthcare providers to acquire content for the fast growing mobile platforms,” commented ADHC.

The App Store model has become the standard for all the smartphone platforms, with RIM, Microsoft, Palm, and Google each building a similar way for developers to make apps available, and for users to find them and pay for them. Developers will have to understand which platform’s App store is best to promote their App.

American Diversified Holdings Corporation is developing a platform for the Mobile Health Care Market as the medical profession gears up to go electronic not only for medical records but also for direct patient monitoring and information. ADHC’s mHealth Division will Focus on Mobile Health Care Applications for iPhone™, iPad™, Android™ and Other Mobile Devices. ADHC is developing applications for the iPhone, iPad, Android and Other Mobile Devices tailored for specific ailments and protocols to allow medical professionals to monitor patients, get instant feedback and constantly adjust treatments to allow greater flexibility and response time in meeting individual patient needs. mHealth or mobile Health is a term used for the practice of medical and public health, supported by mobile devices. The term is most commonly used in reference to using mobile communication devices, such as mobile phones for Health Services and information.

Safe Harbor Statement

This press release contains forward looking statements pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements include risks and uncertainties that may cause the company’s plans to change and are in no way intended to guarantee that the company will be successful in executing its plans. American Diversified Holdings common stock currently trades on the over-the-counter “Pink Sheets” under the symbol ADHC. This press release in no way constitutes any recommendation regarding the securities of ADHC or its affiliates. Any person reading this press release is advised that this release should be considered in the light of all facts and circumstances regarding the business and financial condition and prospects of ADHC, and no inference has been made that this release contains all such information.

American Diversified Holdings Corporation
www.americandiversifiedholdingscorporation.com
Email Contact : ir@americandiversifiedholdings.com

Entest BioMedical’s ImenVax(TM) Cancer Vaccine Appears to Slow Tumor Growth in Advanced Canine Cancer Cases Without Hazardous Side Effects

SAN DIEGO, CA–(Marketwire -09/06/12)- Entest BioMedical Inc. (ENTB) a company focused on veterinary biotechnology and veterinary hospital acquisition / operation, announced today that the company’s recent research study conducted on ImenVax™ (Entest’s Immuno-therapeutic cancer vaccine for dogs), ImenVax™ appears to show signs of slowing tumor growth in advanced cases of oral melanoma, while being well tolerated by patients.

“Principal investigators conducting the safety study on ImenVax™ observed the implantation device and vaccine to be very well-tolerated,” stated Entest BioMedical Chairman & CEO David Koos. “There was only one case where the patient had a minor skin irritation. In all of the cases studied the size of the tumors were likely too extensive to allow for objective response with ImenVax™ as single agent therapy. The company’s researchers stated that subjectively, tumor progression was slowed during the period that the implant was present and accelerated after removal in 2 patients. The report recommends that further evaluation in patients with lesser tumor burden is warranted, along with cytokine stimulation.”

Dr. Koos continued, “Our ImenVax™ immune-therapeutic cancer vaccine is designed to treat dogs with oral melanoma while limiting the side effects of treatment. We anticipate that within the next 16 months, we will have the capacity to treat just over 3,000 patients yearly throughout our veterinary clinics.”

A Spokesperson for the Company noted the National Canine Cancer Foundation says one in three dogs will be impacted by cancer. This staggering statistic shows not only the need for a cost effective treatment but also a treatment that is well tolerated. The potential revenue generated per patient is approximately $3,000 according to industry statistics. Management indicates that each veterinary hospital Entest will seek to acquire over the next two years will have a preexisting patient flow of at least 700 cancer patients per year. Once the first 10 veterinary hospitals have been acquired, Entest could possibly see 7,000 treatable canine patients per year at $3,000 per patient. This meaning, should Entest be successful in meeting its veterinary hospital acquisition target numbers [10 facilities], the company could potentially command revenues reflecting as much as $21 million per annum; treating dogs with cancer.

Dr. Koos concluded, “Our ImenVax™ immuno-therapeutic cancer vaccine is being designed to utilize the patient’s own immune system to battle the cancer; potentially making it a less invasive and less traumatic alternative for pet owners than chemotherapy and radiation therapy. Also, the safety study is being conducted on dogs suffering from oral melanoma. We have no intention to simply stop at oral melanoma applications. Entest is working with an incredibly experienced research team in hopes to increase efficacy in extreme cases by the inclusion of cytokine stimulation. We anticipate at some point in the near future, to begin clinical trials as we will ultimately seek USDA or FDA approval to further the reach of our ImenVax™ canine cancer treatment.”

About Entest BioMedical Inc.:

Entest BioMedical Inc. (ENTB) is a developer of veterinary medicines that harness the animal’s own reparative / immunological mechanisms. The company’s products include an immuno-therapeutic cancer vaccine for canines (ImenVax™). The company’s immuno-therapeutic cancer vaccine utilizes an encapsulation device as the vaccine delivery system and requires a simple implant procedure.

Disclaimer

This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Entest BioMedical Inc.
David R. Koos
Chairman & CEO
619.702.1404 Direct
619.330.2328 Fax
Email Contact
www.EntestBio.com